Stoke Therapeutics Q3 net loss widens 92% to $73.64 million

Bitget2026/10/29 20:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Stoke Therapeutics’ third-quarter 2026 net loss widened 92% year over year to $73.64 million.
Revenue rose 6% year over year to $11.26 million for the quarter.
Cash, cash equivalents and marketable securities totaled $358.8 million at September 30, 2026, expected to fund operations into early 2028.
Zorevunersen’s Phase 3 EMPEROR data readout is anticipated in Q3 2027, with a U.S. NDA submission planned for H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610291601BIZWIRE_USPR_____20261029_BW090140) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Stoke Therapeutics Q3 net loss widens 92% to $73.64 million

You may also like

Crypto prices